tiprankstipranks
Advertisement
Advertisement
Zentalis Highlights Promising Azenosertib Data in Ovarian Cancer
PremiumCompany AnnouncementsZentalis Highlights Promising Azenosertib Data in Ovarian Cancer
2M ago
Zentalis: Buy Rating Reiterated as Azenosertib Strategy Advances; $10 Price Target Maintained on De-Risked Dosing and Late-Stage Catalysts
Premium
Ratings
Zentalis: Buy Rating Reiterated as Azenosertib Strategy Advances; $10 Price Target Maintained on De-Risked Dosing and Late-Stage Catalysts
2M ago
Zentalis reports Q1 EPS (50c), consensus (52c)
Premium
The Fly
Zentalis reports Q1 EPS (50c), consensus (52c)
2M ago
Zentalis to present azenosertib preclinical data in TNBC at AACR meeting
PremiumThe FlyZentalis to present azenosertib preclinical data in TNBC at AACR meeting
3M ago
Midday Fly By: CoreWeave inks Anthropic, TSMC reports March sales bump
Premium
The Fly
Midday Fly By: CoreWeave inks Anthropic, TSMC reports March sales bump
3M ago
Zentalis price target raised to $10 from $6 at Guggenheim
Premium
The Fly
Zentalis price target raised to $10 from $6 at Guggenheim
3M ago
Zentalis Pharmaceuticals: Balancing DENALI Momentum and ASPENOVA Visibility Against Pivotal Data and Execution Risk (Hold Rating Maintained)
PremiumRatingsZentalis Pharmaceuticals: Balancing DENALI Momentum and ASPENOVA Visibility Against Pivotal Data and Execution Risk (Hold Rating Maintained)
6M ago
Zentalis provides update, key milestones in 2025, expectations for 2026
Premium
The Fly
Zentalis provides update, key milestones in 2025, expectations for 2026
6M ago
Zentalis Pharmaceuticals Announces Stock Repurchase Agreement
Premium
Company Announcements
Zentalis Pharmaceuticals Announces Stock Repurchase Agreement
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100